Biogen BIIB reported second-quarter earnings of $9.15 per share, which beat the analyst consensus estimate of $7.53 by 21.51%. This is a 57.76% increase over earnings of $5.8 per share from the same period last year.
The company reported quarterly sales of $3.617 billion, which beat the analyst consensus estimate of $3.48 billion by 3.94%. This is a 7.75% increase over sales of $3.357 billion the same period last year.
Biogen also raised 2019 guidance from $28-$29 to $31.50-$32.30 versus a $29.70 estimate.
Biogen shares were trading up 1.59% at $236.17 in Tuesday’s pre-market session. The stock has a 52-week high of $388.67 and a 52-week low of $216.12.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
